Psilocybin for ‘treatment-resistant depression’: an island of hope in an ocean of uncertainty?

sinitta-leunen-08yfmU-PQUU-unsplash

In this blog, UCL MSc students consider an RCT published in the New England Journal of Medicine, which suggests that psilocybin-assisted psychotherapy may help reduce depression in people with severe and enduring illness, but side effects are common and more research is needed to look into longer term effects.

[read the full story...]

Maintenance or discontinuation of antidepressants for depression? Findings from the ANTLER trial

For every 6 people stopping their medication there was one additional relapse compared to those who maintained their antidepressant treatment, suggesting that stopping medication has an increased risk of relapse.

Raphael Rifkin-Zybutz and Sameer Jauhar summarise the recently published ANTLER trial, which explores whether antidepressant maintenance can reduce the risk of relapse in depression.

[read the full story...]

ADHD: which medications are most effective and safe?

Featured

In his debut blog, Franco De Crescenzo summarises a narrative review that finds good evidence for the short-term pharmacological treatment of ADHD.

[read the full story...]

Turn on, or tune out? Is psilocybin assisted therapy close to becoming a first-line treatment for depression?

reproductive-health-supplies-coalition-V4pVBEHKPo0-unsplash

James Rucker and Sameer Jauhar summarise a recent RCT on the effectiveness of psilocybin assisted therapy versus escitalopram assisted therapy for major depressive disorder.

[read the full story...]